Market context: where Cora and Ro Body sit in the 2026 GLP-1 telehealth market Four numbers anchor the head-to-head comparison between Cora Health and Ro Body in 2026: 41.9% US adult obesity prevalence
The GIP component of tirzepatide is what makes this medication particularly special
When fiber is introduced in the equation, it fuels the metabolic rate
HU-6 is a CMA, administered orally once a day, currently under development for the treatment of obesity and related complications, such as T2DM, MASH, severe hypertriglyceridemia, and heart failure with preserved ejection fraction (HFpEF) (120)
Just go back to eating bland, easy foods for a few days
In our bariatric centers in Bern and Pfffikon (Schwyz), we address our patients individual problems and, if necessary, carry out the diagnostic work-up, including a surgical recommendation in my specialized reflux consultation